XML 15 R4.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Income (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Net sales $ 747,049 $ 647,263 $ 2,189,776 $ 1,755,787
Cost of goods sold 309,614 279,952 950,116 778,120
Gross profit 437,435 367,311 1,239,660 977,667
Selling, general and administrative expense 216,150 198,165 655,428 581,119
Research and Development Expense 64,481 59,546 201,784 160,833
Segment profit (loss) 156,804 109,600 382,448 235,715
Interest expense 426 5,728 1,187 17,158
Foreign exchange (gains) losses, net 2,232 776 542 2,478
Marketable Securities, Unrealized (Gain) Loss (4,868,659) (1,580,350) (7,078,753) (3,591,509)
Other Nonoperating Income (Expense) (579) 1,015 16,732 21,517
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 5,022,226 1,684,461 7,476,204 3,829,105
(Provision) benefit for income taxes (1,094,193) (369,637) (1,656,643) (861,940)
Net income attributable to Bio-Rad $ 3,928,033 $ 1,314,824 $ 5,819,561 $ 2,967,165
Basic earnings per share:        
Net income per share basic attributable to Bio-Rad $ 131.75 $ 44.24 $ 195.29 $ 99.75
Weighted average common shares - basic 29,814 29,721 29,800 29,746
Diluted earnings per share:        
Net income per share diluted attributable to Bio-Rad $ 129.96 $ 43.64 $ 192.76 $ 98.46
Weighted average common shares - diluted 30,224 30,128 30,190 30,137